Status and phase
Conditions
Treatments
About
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion and exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
140 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Study Director
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal